CHM 2101 (CDH17 CAR T)
CHM 2101 (CDH17 CAR T) is an optimized 3rd generation CAR T cell therapy that is the first to target CDH17.
- CCHM 2101 was optimized over a decade of development to address the high unmet medical needs of patients with neuroendocrine tumours
- A potent anti cancer antibody that optimally and specifically bound to neuroendocrine tumor cells was developed and through robust target validation, CDH17 was identified as the antigen target
- The CDH17 CAR T was optimized as a 3rd generation construct with both CD28 and 41BB costimulatory domains
- CHM 2101 preclinical evidence have demonstrated a unique potency for solid tumours with complete eradication of tumour cells with no relapse
Preclinical studies also demonstrated no toxicity to normal tissues.
Although CDH17 is known to be expressed on normal epithelial cells, the CDH17 CAR T cells only infiltrated the tumour cells, sparing the normal cells, even when they expressed CDH17.
In normal cells, CDH17 is inaccessible as it is hidden beneath tight junctions that reinforce the barriers of normal cells while in cancer, CDH17 upregulation results in exposure of the CDH17 on the cancer cells allowing the CAR T to detect and bind to it.
With the evidence of high CDH 17 expression in solid tumours, CHM 2101 is being studied in neuroendocrine tumours as well as in gastrointestinal (GI) cancers such as colorectal, pancreatic and gastric cancer.